Compare Moderna, Inc. (MRNA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard S&P 500 ETF — how do they compare? Moderna, Inc. trades at $221.1 (market cap $78.65B), while Vanguard S&P 500 ETF trades at $715.12 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 22.9× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Vanguard S&P 500 ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Vanguard S&P 500 ETF for 55 Days on average.
| MRNA | VOO | |
|---|---|---|
Market Cap | $78.65B | $1.80T |
Volume | 37,373,437 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $203.46 | $716.17 |
52-Week Low | $22.36 | $580.93 |
Typical Hold Time | 59 Days | 55 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
VOO trades at $713.62, down slightly by 0.11% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 68.50 suggesting mild overbought conditions. Recent news highlights VOO's role in long-term wealth building through capital growth rather than dividends, with one article positioning it as a recession-resistant holding.
VOO offers diversified exposure to S&P 500 companies with strong institutional backing. Key risks include market volatility from interest rate uncertainty and potential earnings growth slowdown from 35% to 15% in 2027. The ETF remains a core holding for long-term investors despite short interest increasing 46.9% in September.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
